Mucocutaneous Dissemination of Acyclovir-Resistant Herpes Simplex Virus in a Patient with AIDS

Marks, G. Lynn; Nolan, Patrick E.; Erlich, Kim S.; Ellis, M N

doi:10.1093/clinids/11.3.474

Cited by 42 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, resistant HSV had also been recovered from patients (26,42,104,105), but these viruses were not associated with, nor did they cause, progressive disease in the immunocompetent patient (7). However, the emergence of drug-resistant herpesviruses in the immunosuppressed patient did result in progressive disease, as described in the articles accompanying the editorial (15,46,47), as well as elsewhere (90). In the intervening years since the Hirsch and Schooley editorial, greater attention has been paid to rapid detection of drug-resistant clinical isolates and the clinical importance of infections associated with drug-refractory herpesviruses in immunosuppressed patients.…”

Section: Introductionmentioning

confidence: 99%

"The end of innocence" revisited: resistance of herpesviruses to antiviral drugs

Field¹,

Biron²

1994

Clin Microbiol Rev

171

109

View full text Add to dashboard Cite

In the past 4 years, interest in drug-resistant herpesviruses has evolved from the realm of academic laboratory studies to that of great clinical importance. Recurrent and persistent infections due to the herpes simplex viruses, varicella-zoster virus, and human cytomegalovirus have been an unwelcome consequence of immunosuppression in graft recipients, cancer patients, and those suffering from AIDS. Treatment of these infections with the available antiviral drugs, such as acyclovir, ganciclovir, and foscarnet, has resulted in both clinical benefit and the emergence of drug-resistant variants. In addition, the role of Epstein-Barr virus is being clarified for an array of disease syndromes, and therapeutic approaches are beginning to emerge. In the present review, the emergence and clinical importance of drug resistance among the herpesviruses have been explored. Furthermore, particular attention has been focused on our understanding of the mechanisms of drug resistance and how that understanding will guide us in the development of more effective antiviral drugs and drug usage.

show abstract

Section: Introductionmentioning

confidence: 99%

"The end of innocence" revisited: resistance of herpesviruses to antiviral drugs

Field¹,

Biron²

1994

Clin Microbiol Rev

171

109

View full text Add to dashboard Cite

show abstract

“…Since the first report of resistance to acyclovir in an immunocompromised, herpes simplex virus (HSV)-infected patient in 1982 (14), numerous other reports of resistance have been published (1, 6, 9, 11, 12, 22-24, 42, 53, 56, 58, 60, 69, 77). In the setting of patients with AIDS, resistance has clearly become clinically significant in HSV type 1 (HSV-1) and HSV-2 (2,7,8,27,33,50,55,61,63,65), cytomegalovirus (CMV) (4,19,25), and varicella-zoster virus (VZV) (35,40,46,57).…”

Section: Introductionmentioning

confidence: 99%

Resistance of herpesviruses to antiviral drugs

Chatis

Crumpacker

1992

Antimicrob Agents Chemother

100

View full text Add to dashboard Cite

“…The recovery of acyclovir-resistant HSV among clinical isolates from patients with normal immunity has not been associated with the progression of clinical disease (5,13,29). However, acyclovirresistant HSV has been recovered more frequently from immunocompromised patients and has resulted in locally progressive mucocutaneous lesions (5,13,18,19,29,31,34). The majority of acyclovir-resistant HSV clinical isolates are also cross-resistant to penciclovir (39,60).…”

mentioning

confidence: 99%

Sodium Lauryl Sulfate Increases the Efficacy of a Topical Formulation of Foscarnet against Herpes Simplex Virus Type 1 Cutaneous Lesions in Mice

Piret

Désormeaux

Cormier

et al. 2000

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The influence of sodium lauryl sulfate (SLS) on the efficacies of topical gel formulations of foscarnet against herpes simplex virus type 1 (HSV-1) cutaneous infection has been evaluated in mice. A single application of the gel formulation containing 3% foscarnet given 24 h postinfection exerted only a modest effect on the development of herpetic skin lesions. Of prime interest, the addition of 5% SLS to this gel formulation markedly reduced the mean lesion score. The improved efficacy of the foscarnet formulation containing SLS could be attributed to an increased penetration of the antiviral agent into the epidermis. In vitro, SLS decreased in a concentration-dependent manner the infectivities of herpesviruses for Vero cells. SLS also inhibited the HSV-1 strain F-induced cytopathic effect. Combinations of foscarnet and SLS resulted in subsynergistic to subantagonistic effects, depending on the concentration used. Foscarnet in phosphate-buffered saline decreased in a dose-dependent manner the viability of cultured human skin fibroblasts. This toxic effect was markedly decreased when foscarnet was incorporated into the polymer matrix. The presence of SLS in the gel formulations did not alter the viabilities of these cells. The use of gel formulations containing foscarnet and SLS could represent an attractive approach to the treatment of herpetic mucocutaneous lesions, especially those caused by acyclovir-resistant strains.

show abstract

Mucocutaneous Dissemination of Acyclovir-Resistant Herpes Simplex Virus in a Patient with AIDS

Cited by 42 publications

References 0 publications

"The end of innocence" revisited: resistance of herpesviruses to antiviral drugs

"The end of innocence" revisited: resistance of herpesviruses to antiviral drugs

Resistance of herpesviruses to antiviral drugs

Sodium Lauryl Sulfate Increases the Efficacy of a Topical Formulation of Foscarnet against Herpes Simplex Virus Type 1 Cutaneous Lesions in Mice

Contact Info

Product

Resources

About